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Biosimilar insulin as an alternative  
for the original products
ABSTRACT 
The medical knowledge makes a great progress in 
methods of treating diseases that makes our life much 
longer. Diabetes is a typical disease of civilization af-
fecting more and more people all over the world. The 
cost of insulin therapy constitutes a great part of all 
expenditures associated with the treatment of patients 
with diabetes mellitus type 1 and type 2. Nowadays, 
when the patents covering biological insulins expire, 
new possibilities of using biosimilar insulins in treating 
diabetic patients appear. What is more, this group of 
products seems to be very promising.
The authors describe, how the biopharmaceuticals and 
biosimilar drugs started to be used in the treatment. 
They present the similarities and differences between 
the biosimilars, original drugs and also generic prod-
ucts, with taking special interest in immunogenicity 
and the safety profile. The authors also point out the 
potential advantages and the risk of possible side ef-
fects of using biosimilar insulins in patients suffering 
from diabetes. (Clin Diabetol 2016; 5, 4: 123–126)
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Introduction
The medicine makes a great progress in the treat-
ment methods that significantly prolong our life. Un-
fortunately, this involves also a greater consumption 
of drugs required to balance homeostasis disorders.
 A typical example of a disease of civilization is 
diabetes mellitus which affects more and more people. 
Only in Poland, 3 million people suffer from diabetes 
mellitus and they require treatment with antidiabetic 
drugs, including insulin. At first, for several dozen years, 
insulin was obtained from the pancreas of beef and 
pork. Insulins obtained by this method were not in full 
compliance with human insulin. The amount of insulins 
obtained in this manner was limited. In many cases, 
this type of insulins were inducing allergies. 
In the eighties of the last century, human insulins 
obtained by genetic engineering appeared on the 
market. These drugs were thoroughly tested in terms 
of their action and induced side effects. 
Currently, biosimilar drugs are available on the 
market, including insulin. The following paper presents 
what kind of medications they are, what type of side 
effects are associated with their use, and what can be 
their importance in treatment. 
Biopharmaceutical — what is it?
Biopharmaceutical, also known as biological medi-
cal products were introduced to the medical market 
in the eighties of the twentieth century. These drugs 
contain one or few substances produced or secreted 
by live cells [1]. Usually, these products replace or sup-
plement the naturally produced proteins. This group 
includes products obtained by modern biotechnologi-
cal methods, such as recombinant proteins, vaccines, 
monoclonal antibodies, gene transfer products and 
products for somatic cell therapy, and also synthetic 
polypeptides, synthetic oligonucleotides prepared by 
chemical synthesis as well as conventional biological 
drugs (e.g. blood products, toxins and sera) which are 
not obtained by advanced biotechnological methods 
[2]. These drugs are produced by biotechnological 
methods of DNA recombination, and contrary to 
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chemical drugs, they have a complex structure which 
is difficult to be fully characterized with physical and 
chemical methods. The differences in the structure 
with a higher reaction order may entail differences in 
the biological activity of active substances with the 
same chemical formula, and thus, cause differences in 
the effectiveness and safety of medicinal products [3].
The group of first-generation biopharmaceutical in-
cludes products that are copies of endogenous human 
proteins, e.g. insulins, growth hormone or erythropoi-
etins. The first biopharmaceutical officially registered 
and approved for therapeutic use was human insulin 
produced from recombined DNA. Humulin (developed 
by Genentech, produced and licensed by Eli Lilly and 
Company) is available on the market since 1982. After-
wards, a human recombined erythropoietin was used, 
and then monoclonal antibodies as well as cytokines. 
The latest generation of biopharmaceutical con-
sists of antisense molecules which can interfere with 
the communication process that leads to the produc-
tion of unwanted proteins by cells. The first drug of 
this group — antisense oligonucleotide, was used in 
the treatment of retinitis caused by cytomegalovirus 
infection in patients suffering from Acquired Immune 
Deficiency Syndrome [4].
It is estimated that currently, there are more than 
130 biopharmaceutical and hundreds are under re-
search. In order to introduce a medicinal product into 
the market, it is required to submit chemical-pharma-
ceutical and biological, pharmacological-toxicological 
and clinical documentation to relevant registration 
authorities. A full range of data is required only in rela-
tion to the original products. After the expiration of the 
period of data exclusivity, their copies (that is generic 
drugs) can be put on market without the need to sub-
mit the results of pharmacological, toxicological and 
clinical tests, except for the bioequivalence study [2].
Biosimilar drugs — what is it and how  
do they differ from the original drugs?
Currently, a lot of biological drugs of first genera-
tion cease to be covered by a patent and thus, the 
global market of biological products opens for the 
so-called biosimilar drugs. 
The term “biosimilar” means “a new biological 
product similar (but not identical) to the already ap-
proved drug”. Such proteins cannot be and never are 
100% identical to the original protein. It is possible to 
fully characterize the structure and production process 
of small-molecule compounds, however it is impossible 
in case of large biological molecules, e.g. products 
based on the structure of monoclonal antibodies. The 
produced medicine cannot be fully biotechnologically 
characterized, and it means that it is impossible to ex-
actly reproduce the original drug [5–8]. There is a clear 
difference between the generic drugs and biosimilars. 
The commonly used term “biosimilar” arises from a dif-
ficulty to evidence an equivalent efficiency and safety 
of these drugs, as in case of generic drugs. The protein 
structure makes it impossible to show the biological 
equivalence only by methods applied to generic drugs, 
in particular those with small molecular weight [2].
The distinction between biosimilar and generic 
drugs is of vital importance for practical reasons and 
physicians should be well-trained in this scope. Each 
physician should be aware of the fact that these drugs 
are not exact copies of the original preparations, as 
it is in case of generic chemical drugs, but these are 
biotechnological drugs, the structure of which and 
their function only imitate the originals. The reason 
for the differences is, in particular, the fact that each 
time another cell line, another production and purifi-
cation process in their preparation is used. As already 
mentioned above, it is possible to copy chemical drugs 
because they have a specific structure that can be de-
scribed as a chemical formula. In contrast, the unique 
multidimensional structure of proteins constituting 
biopharmaceuticals cannot be described by a formula, 
even the most complex. Likewise, it is impossible to fully 
reproduce the mechanisms of action of drugs, even if the 
same type of cells is used for production of a particular 
pharmaceutical. Therefore, we should always expect 
that some differences will occur in the pharmacokinetic 
and pharmacodynamics properties of biosimilar drugs in 
comparison to the original medicines. It was confirmed, 
for example, by comparing the content of the prepara-
tion and potential of various recombined erythropoietins 
alfa produced outside the EU and USA [9, 10]. 
The safety profile of biosimilars is obviously dif-
ferent from the original drugs [11]. Generally, all 
therapeutic proteins elicit, to some extent, the immune 
response. Immunogenicity is one of the most significant 
features determining the safety of a biological product. 
The immune reaction after administration of a drug is 
unpredictable and very diverse (sometimes even life-
threatening). There are many factors determining the 
occurrence of immunogenicity: individual characteris-
tics of the patient, progression of a disease, and even 
the therapy itself. Due to the fact, that the biosimilar 
drugs can be potentially immunogenic (as opposed to 
the small-molecule pharmaceuticals), even slight struc-
tural changes can significantly affect the immunogenic 
potential of the final product [12, 13].
It also seems that it would be a good solution if 
biosimilar drugs get another international name than 
the originals. This would prevent an automatic substitu-
tion of these substances, and the drugs would have to 
be subject to a full cycle of preclinical and clinical tests 
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before their marketing. Thus, it would have a positive 
impact on the safety of their use. Marking of biosimilar 
drugs on their packaging should also clearly distinguish 
biosimilars from the original drugs [8]. 
In the current context of increasing financial con-
straints and due to expiration of patents protecting the 
biological drugs, biosimilar pharmaceuticals certainly 
constitute a group of products with a great future. It 
seems that they offer high quality and clinical efficacy 
together with a significantly lower price than the origi-
nals. Prevalence of these drugs may significantly lower 
the costs of treatment and contribute to savings in the 
health care systems. That is why, wide availability of 
biosimilar drugs may bring benefits not only in terms 
of health but also economic advantages. 
Biosimilars are already used in many fields of 
medicine, such as endocrinology, rheumatology, gas-
troenterology, neurology, haematology or oncology. 
The representatives of this type of drugs were registered 
for the first time in Europe in 2006. That was Omnitrope 
(equivalent of Genotropin) and Valtropin (equivalent of 
Humatrope) for treatment of short in stature. In subse-
quent years, biosimilars of recombined human eryth-
ropoietin, G-CSF granulocyte colony-stimulating factor 
(filgrastim) and human growth hormone (somatropin) 
were also made available. In 2013, a biological biosimilar 
drug containing monoclonal antibody was registered for 
the first time. It contains infliximab which has been used 
in treatment for several years already, e.g. rheumatoid 
arthritis, ankylosing spondylitis or psoriasis [14].
Biosimilar versions of several drugs, including re-
combined glucagon, recombined salmon calcitonin and 
hyaluronidase have been also admitted to the United 
States market.
Biosimilar insulin — will they dominate 
the insulin market?
A steady increase in the incidence to diabetes mel-
litus is observed in the world, in particular diabetes 
mellitus type 2 — the disease of civilization. After the 
90’s, since insulin was discovered, the insulin market is 
significant and it growths vigorously. It was estimated 
that the worldwide insulin sales amounted to $16.7 bil-
lion in 2011, about 12,5% more than in 2010. This sum 
exceeded $8.3 billion in the USA and it has increased by 
14.9% since 2010 [15]. The costs of treating diabetes 
are very high. In 2011, they exceeded $201 billion in 
the United States and $465 billion around the world 
[16]. The cost of insulin therapy constitutes a great 
part of all expenditures associated with the treatment 
of patients with type 1 and type 2 diabetes mellitus. 
Therefore, it seems that the biosimilar insulin can be 
the future of diabetes treatment. 
The patent protection of numerous insulins, includ-
ing short-acting and long-acting equivalents, such as 
insulin aspart, lispro and glargine expired or will expire 
in the near future.
Biosimilar insulins are biological modifications in 
which, the active substance is obtained from a living 
organism by DNA recombination methods or methods 
of control of gene expression. Any doubts that the 
biosimilar insulin is not a generic insulin should be dis-
pelled, contrary to what some practitioners think. The 
differences between the generic and biosimilar insulin 
can be the same, as described above with regard to the 
generic and biosimilar products as such. The remarks 
concerning the safety of biosimilar insulin are of vital 
importance; immunogenicity (a significant issue in case 
of a chronic use of the product) and side effects, e.g. 
a risk of hypoglycaemia, disproportionate to the dose 
of the medicine.
In some countries that do not comply with the 
European standards, biosimilar copies of insulin are 
already widely available, e.g. Basalog based on the 
original drug - glargine, produced by Biocon in India, 
with the efficacy and safety similar to Lantus in patients 
with diabetes mellitus type 1 [17]. Biosimilar insulins 
are also used in China, Pakistan, Peru, Thailand and 
Mexico. In these countries, there are no special restric-
tions concerning marketing the biosimilar products. 
In 2007, Marvel Lifesciences Private Ltd. (Mum-
bai, India) started its endeavours to obtain an ap-
proval of EMA (European Medicines Agency) for three 
biosimilar insulins: fast-acting insulin (Marvel Rapid), 
long-acting isophane insulin (Marvel Long) and mix 
(30% of soluble insulin and 70% of long-acting in-
sulin). However, the documentation submitted by 
the manufacturer was not complete. There was no 
exact specification of these insulins. Subsequently, 
Marvel withdrew from the registration procedure 
concerning these products.
A biosimilar drug Abasaglar is available in the Eu-
ropean Union (the former name was Abasria; the name 
was changed in 2014 to Abasaglar) and it contains 
an active substance — insulin glargine. The European 
Medicines Agency (EMA) issued a positive opinion on 
this product in September 2014 [18]. The reference 
medicine for Abasaglar is insulin Lantus. The method 
of DNA recombination is used for production of the 
active substance of Abasaglar. It is created by bacteria 
to which a gen (DNA) that enables production of glar-
gine was introduced. A case of a patient who has been 
taking glargine for years without any allergic reaction 
and who had anaphylaxis after taking biosimilar insulin 
was described in 2014. Basophil degranulation in vitro 
caused by a biosimilar product suggests the occur-
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rence of allergic reactions to one or more ingredients 
of the biosimilar drug, but not the parent one. After 
discontinuation of the biosimilar drug treatment and 
taking back the previously used glargine, the allergic 
reaction of the patient completely subsided. It proves 
the immunogenicity of the biosimilar drug [19].
It seems that the benefits of using biosimilar insulin, 
in particular a lower cost of therapy, outweigh the risk of 
any possible side effects. Nevertheless, lack of long-term 
randomized, blinded, trials constitutes a great problem. 
Unfortunately, there is no evidence based medicine on 
the efficacy and safety of using biosimilar insulins, so far. 
Most of the available publications on the subject matter 
were sponsored by pharmaceutical companies produc-
ing insulin. The companies frequently underestimate 
the need for a thorough and transparent interpretation 
of results of clinical researches. In case of insulin, the 
safety of the product is hard to be assed based on the 
animals testing, and what is more, on the basis of in 
vitro studies. The European Medicines Agency requires 
clinical tests in humans for registration purposes. On the 
one hand, it increases the safety of a product and on the 
other hand, it limits the number of drugs released. It is 
clear that the most desirable would be clinical studies 
comparing the efficacy and safety of a biosimilar drug 
with the original medicine. 
In the coming years, most of patent agreements 
for the production of human insulins will expire. It will 
fully open the medical market to biosimilar insulins 
as an alternative to the original products. Abasaglar 
(named Basaglar in the USA) is produced by Eli Lilly and 
Boehringer Ingelheim, however it is well-known that 
other pharmaceutical concerns, such as Merck, Biocon 
(Mylan) and Sanofi are already working on biosimilar 
insulins (glargine, lispro). In the next few years, at least 
several biosimilar insulins will be available on the mar-
ket. It is estimated that ultimately, about 40 biosimilar 
insulin will be put on the market [20]. 
Summary
With spreading the use of biosimilar insulins, it will 
be possible to lower the costs of treatment, increase 
the availability of insulin therapy among patients with 
type 1 and type 2 diabetes mellitus, and the choice of 
medicines will be large. Nevertheless, due to the safety 
of patients, the rules for the registration of biosimilar in-
sulins and monitoring their side effects should be clearly 
defined and strictly observed. Long-term observations 
of not only the efficacy but also the safety of biosimilar 
products (including insulins) are required. Clinicians who 
deal with insulin therapy every day should be aware of 
both the advantages and disadvantages (in particular, 
the potential immunogenicity) of biosimilar insulins. 
The term “biosimilar drugs” is a mental shortcut mean-
ing in fact “biological drugs registered on the basis of 
proving the biological similarity to the reference drug”. 
Therefore, we should always remember that biosimilar 
drugs are not bioidentical with the originals. 
REFERENCES
1. Commission Directive 2003/63/EC of June 2003 amending Direc-
tive 2001/83/EC of the European Parliament and Council on the 
Community code relating to medicinal products for human use. 
2. Zieliński W. Biotechnologia. Monografie 2009; 5: 57–74.
3. Bogiel M, Marzec A. Leki biopodobne — pełnowartościowe, 
nowoczesne preparaty biotechnologiczne. Terapia i Leki 2008; 
35/57/2: 40–50.
4. Lanao JM, Briones E, Colino CI. Recent advances in delivery 
systems for anti-HIV1 therapy. J Drug Target 2007; 15: 21–36.
5. Sekhon BS, Saluja V. Biosimilars : an overview. Biosimilars 2011; 
1: 1–11.
6. Roger SD. Biosimilars: current status and future directions. Expert 
Op Biol Ther 2010; 10: 1011–1018.
7. Kresse GB. Biosimilars — science, status, and strategic perspective. 
Eur J Pharm Biopharm 2009; 72: 479–486.
8. Nowicki M, Zimmer-Nowicka J. Biofarmaceutyki oryginalne 
i leki biopodobne — co należy o nich wiedzieć, aby zapewnić 
bezpieczeństwo leczenia? Onkol Prakt Klin 2007; 3: 120–127.
9. Schmidt CA, Ramos AS, da Silva JEP, Fronza M, Dalmora SL. 
Activity evaluation and characterization of recombinant human 
erythropoietin in pharmaceutical products. Arg Bras Endocrinol 
2003; 47: 183–189.
10. Schellekens H. Follow-on-biologics: challenges of the “next gen-
eration”. Nephrol Dial Transplant 2005; 20 (suppl 4): iv31–36.
11. Schellenkens H. Biopharmaceuticals and biosimilars, unraveling 
the complexity. EJHP Practice 2006; 12: 13.
12. Crommelin D, Bermejo T, Bissig M et al. Biosimilars, generic ver-
sions of the first generation of therapeutic proteins: do they exist? 
Contributions to Nephrology 2005; 149: 287–294.
13. Crommelin DJ, Storm G, Verrik R, de Leede L, Jiskoot W, Hennink WE. 
Shifting paradigms: biopharmaceuticals versus low molecular 
weight drugs. Int J Pharmaceutics 2003; 266: 3–16. 
14. EMA 2013.  ht tp : / /www.ema.europa.eu /ema/ index .
jsp?curl=pages/medicines/002778/human_med_001677.
jsp&mid=WC0b01ac058001d124.
15. Diabetes drug and device industry 1Q12 finacial model. 
San Francisco, Calif., Close Concerns, Inc. 2012.
16. International Diabetes Federation: Healthcare expenditures. 
http://www.idf.org/diabetesatlas/5e/healthcare-expenditures 
[dostęp: 17.06.2012].
17. Biocon. Biocon launches BASALOG — long lasting basal insulin 
for type 1&type2 diabetics. http://www.biocon.com/biocon_inv_
press_relaeses_29may2009.asp [dostęp: 04.2015].
18. European Commission grants Lilly and Boehringer Ingleheim’s 
insulin glargine product marketing authorization in Europe. 
Press release of Eli Lilly and Boehringer Ingelheim, September 10, 
2014. http://www.boehringeringelheim.com/news/news_releases/ 
/press_relaeses/2014/10_september_2014_insulin_glargine.html.
19. Garcia-Nares H, Leyva-Carmona MI, Perez-Xochipa N et al. A hy-
persensitivity reaction to a biosimilar insulin glargine. J Diabetes 
2014; 7: 155–157.
20. Rader RA. An analysis of the US biosimilars development pipeline 
and likely market evolution. Bio Process Int 2013; 11: 16–23.
